Enochian Bio's Shares Rise 54% After FDA Accepts Pre-IND Request for Potential HIV Cure
Source: Streetwise Reports  (6/14/21)
Shares of Enochian Biosciences Inc. traded higher after the company reported that the U.S. Food and Drug Administration accepted a pre-investigational new drug request for a potential functional cure or treatment for human immunodeficiency virus. More >

Sorrento's COVID Test Approved in Mexico
Source: Streetwise Reports  (6/9/21)
This and other recent developments involving Sorrento Therapeutics' pipeline and partners are covered in a Dawson James Securities report. More >

Tilray Shares Climb Higher on Roll Out of New Medical Cannabis Brand Symbios
Source: Streetwise Reports  (6/9/21)
Tilray Inc. shares traded 11% higher after the company reported the launch of a new medical cannabis brand, Symbios, designed to provide medicinal users with a broader spectrum of formats and cannabinoid potencies at improved price points. More >

Promising Psychedelic Drug Trials Show Potential for a New Biotech Boom
Source: McAlinden Research for Streetwise Reports  (6/4/21)
McAlinden Research Partners notes that continued advances in psychedelic therapies show potential to drive an investment boom that could reshape the future of medicine and mental health therapies. More >

Kindred Bio Shares Rise 29% after Achieving 100% Survival Rate in Canine Parvovirus Study
Source: Streetwise Reports  (6/3/21)
Kindred Biosciences Inc. shares reached a new 52-week high after the company reported its parvovirus monoclonal antibody, KIND-030, demonstrated highly positive results in preventing deaths in dogs infected by parvovirus. More >

Drug Repurposing Firm Launches Clinical Research Program in Pancreatic Cancer
Source: Streetwise Reports  (6/3/21)
Based on various positive preclinical and clinical studies, Algernon Pharmaceuticals is pursuing Ifenprodil as a potential treatment for pancreatic tumors. More >

Biotech Receives National Cancer Institute Resources Award for Ovarian Cancer Vaccine Program
Source: Streetwise Reports  (6/2/21)
The award and other recent developments at Anixa Biosciences are covered in an H.C. Wainwright & Co. report. More >

Constellation Pharma Shares Sparkle on $1.7 Billion Buyout Offer
Source: Streetwise Reports  (6/2/21)
Shares of Constellation Pharmaceuticals Inc. traded 65% higher after the company reported it entered into an agreement to be acquired by MorphoSys AG in an all-cash transaction for $34 per share. More >

Analyst: Clinical News, Catalysts Portend 'Rich' Q2/21 for Biopharma
Source: Streetwise Reports  (5/26/21)
Second-quarter clinical events related to Anavex Life Sciences' pipeline are summarized in a Dawson James Securities report. More >

Analyst: New Data Show Cancer Therapeutic 'Continues to Deliver Benefit'
Source: Streetwise Reports  (5/26/21)
Data from two of Oncternal Therapeutics' clinical trials in oncological indications are discussed in an H.C. Wainwright & Co. report. More >

Verastem Shares Rise 25% as FDA Issues Breakthrough Therapy Designation for Ovarian Cancer Drug
Source: Streetwise Reports  (5/24/21)
Verastem Inc. shares reached a new 52-week high after the company reported its VS-6766 in combination with defactinib was granted breakthrough therapy designation by the FDA for treatment of recurrent low-grade serous ovarian cancer. More >

Biopharma Has 'Trials Progressing; Multiple 2022 Data Readouts' Including for PTSD
Source: Streetwise Reports  (5/19/21)
Updates on Aptinyx's three central nervous system drug candidates and the company's Q1/21 earnings are delivered in an H.C. Wainwright & Co. report. More >

Analyst Highlights Two Key Catalysts for Biotech
Source: Streetwise Reports  (5/19/21)
The biopharma aTyr's upcoming drug application and clinical-trial results are discussed in a ROTH Capital Partners report. More >

Sarepta Therapeutics Posts Positive Results in Duchenne Muscular Dystrophy Study
Source: Streetwise Reports  (5/18/21)
Sarepta Therapeutics shares traded 8% higher after the company reported its investigational gene therapy SRP-9001, used for treating Duchenne's Muscular Dystrophy, had "positive 12-week expression and safety results." More >

Apellis Gains FDA Approval for Empaveli to Treat Chronic Blood Disorder
Source: Streetwise Reports  (5/17/21)
Shares of Apellis Pharmaceuticals Inc. traded 20% higher after the company reported it received U.S. FDA approval for EMPAVELI (pegcetacoplan) for use in treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare, chronic life-threatening blood disorder. More >

Analyst: Biotech Expecting a 'Catalyst-Rich' Second Half of the Year
Source: Streetwise Reports  (5/13/21)
An H.C. Wainwright & Co. report discusses Gritstone Bio's recent earnings and significant corporate events as the firm plans to release data on cancer and COVID-19 vaccines later this year.
More >

Pharma Developer Finds Ifenprodil Reduces Interleukin 6 in Phase 2b/3 COVID Trial
Source: Streetwise Reports  (5/13/21)
Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough. More >

Twist Bioscience Shares Wind Higher After Firm Posts 62% YoY Increase in Q2 Revenue
Source: Streetwise Reports  (5/7/21)
Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million. More >

Biotech's Gene Therapy Assets Put It 'Ahead of the Pack'
Source: Streetwise Reports  (5/5/21)
Sio Gene Therapies' focus and strategic portfolio are discussed in an H.C. Wainwright & Co. coverage initiation report. More >

BioNTech Shares Gain 11% on Filing COVID-19 Vaccine Expanded Use Request to EMA in Children Ages 12 to 15
Source: Streetwise Reports  (5/3/21)
BioNTech shares established a new 52-week high price after the company reported that together with its partner Pfizer it has filed a request to expand Conditional Marketing Authorization of COMIRNATY® in the EU to adolescents ages 12 to 15 for its mRNA-based SARS-CoV-2 vaccine.
More >

Galera Posts Positive Data from Phase 1/2 Pancreatic Cancer Trial
Source: Streetwise Reports  (4/29/21)
Galera Therapeutics shares traded 25% higher after the company reported new data from its Phase 1/2 pilot study of dismutase mimetic GC4419 that when used in combination with radiation therapy was shown to nearly double median overall survival time in patients with locally advanced pancreatic cancer. More >

Biopharma Study Shows Safety of Stem Cell Therapy in Severe COVID-19 Patients
Source: Streetwise Reports  (4/28/21)
The clinical trial, in which Sorrento Therapeutics established safety, and the company's next steps for this potential treatment are summarized in a Dawson James Securities report. More >

ADMA Biologics Granted FDA Approval to Boost IVIG Production by 50%
Source: Streetwise Reports  (4/28/21)
ADMA Biologics shares traded 9% higher after the company received FDA approval for increased intravenous immune globulin production scale, allowing the firm to increase manufacturing capacity from 400,000 to 600,000 liters and achieve peak revenues of greater than $300 million. More >

Aldeyra's Drug Meets All Key Endpoints in Phase 3 Allergic Conjunctivitis Trial
Source: Streetwise Reports  (4/27/21)
Aldeyra Therapeutics shares traded 33% higher after the firm reported that reproxalap significantly met all primary and secondary endpoints in its Phase 3 allergic conjunctivitis study. More >

Ocugen Reports $100 Million Direct Share Offering at Market Premium from Institutional Investors
Source: Streetwise Reports  (4/23/21)
Ocugen Inc. shares traded up as much as 47% before closing just 3.66% higher after the company announced a $100 million registered direct offering of common stock priced at a $10 per share, which represents a premium to the market price. More >